Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study
Table 4
Comparison of subgroups according to cause of anti-PD-1 discontinuation in the anti-PD-1 cohort, University Hospital of Bordeaux, 2019.
All patients, n = 65
CR group, n = 25
PR/SD group, n = 12
AEs group, n = 28
value1
Median follow-up after introduction of treatment months (range)
36.5 (4.6–62.4)
40.5 (21–54.3)
40.4 (25.4–62.4)
29.7 (4.6–52.1)
0.015
Median TOT months (range)
14.1 (0.7–51.2)
16.8 (7.6–34.9)
21.2 (10.1–51.2)
7.2 (0.7–30.2)
<0.001
Median follow-up after discontinuation months (range)
15.7 (2.5–45.1)
22.3 (6.2–42.3)
11.3 (5.9–31.5)
12.7 (2.5–45.1)
0.144
Median time to best response months (range)
5.6 (0.7–32)
6.2 (2.5–21.4)
4.9 (2.8–27.8)
4.5 (0.7–32)
0.537
Relapses, n (%)
12 (18.5)
3 (12)
2 (16.7)
7 (25)
0.491
Median time before relapse months (range)
9 (1.9–40.9)
9.3 (4–11.8)
11.9 (10.9–12.8)
7.1 (1.9–40.9)
0.308
Second-course after relapse, n (%)
9 (13.8)
3 (12)
2 (16.7)
4 (14.3)
1
1 value obtained with Kruskal–Wallis and Fisher tests for three groups equality. Abbreviation: TOT: time on treatment; CR, complete response; PR, partial response; SD, stable disease.
